Amgen stock breakout attempt: Upside targets to watch

Traders Union
All News
Stocks
Amgen gains 3.5% on trial results

Highlights

Amgen announced that its Phase 3 OASIZ 301 trial for dazodalibep in systemic Sjögren’s disease achieved statistically significant and clinically meaningful results at Week 48.
Detailed data from the successful trial will be presented at an upcoming medical meeting as the company targets regulatory progression for this late-stage asset.
Shares of Amgen rose 3.5% to $407.42 with technical indicators showing bullish momentum and a likely consolidation in the $398.56 to $416.28 range over the next 2 to 3 days.

Clinical trial success boosts Amgen outlook and investor optimism

Amgen has reported that its Phase 3 OASIZ 301 study of dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in disease activity at Week 48, according to Investing.com and Prnewswire. This clinical milestone validates the efficacy of dazodalibep and strengthens expectations for regulatory advancement, energizing investor sentiment around Amgen’s late-stage pipeline. The company also plans to present detailed study data at an upcoming medical meeting, further maintaining market focus on its therapeutic innovation.

Overbought signals strengthen as technical support holds firm

AMGN is currently holding above the MA-20 ($386.75) and MA-50 ($381.63) on the hourly chart, as well as the MA-200 ($360.61) on the daily. Immediate support is seen at the Ichimoku Kijun level of $390.94. RSI is elevated at 82.44, and both MACD and ADX indicate buying conditions, while Stoch RSI, CCI, and Bull/Bear Power all reflect overbought territory and strong intraday buyer momentum. The Awesome Oscillator is neutral and does not signal a directional bias.

Consolidation likely as breakout and pullback risks diverge

Over the next 2–3 days, AMGN is expected to trade within a range of $398.56 to $416.28, with a 74% probability of an upward move and a 26% chance of pullback. The baseline scenario is consolidation inside this volatility band. A breakout above $416.28 could trigger further upside, while a fall below $398.56 may lead to additional downside pressure.

Viktoras Karapetjanc, Traders Union expert, sees continued strength in Amgen on the back of positive late-stage clinical data and robust technical momentum. He believes investor sentiment is firmly supported by the successful Phase 3 readout, elevating expectations for regulatory forward steps and future growth. AMGN remains above key moving averages, and buying momentum dominates despite signs of overbought conditions. The baseline outlook is bullish consolidation, with upside favored unless support at $398.56 fails. "Amgen’s clinical breakthrough and strong market positioning make the current uptrend likely to continue in the near term."

Previously it was reported that Amgen shares were testing key resistance following positive Phase 3 results in Sjogren’s disease, with analysts noting a generally bullish chart structure. The current breakout above major moving averages and continued overbought signals now put focus on whether AMGN can maintain momentum through the projected $398.56–$416.28 trading range in the coming sessions.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.